A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
- Conditions
- Spontaneous Bacterial Peritonitis
- Interventions
- Registration Number
- NCT04208763
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Brief Summary
Study population: A total of 90 consecutive patients of decompensated cirrhosis of any etiology, presenting to the Institute of Liver and Biliary Sciences with SBP with septic shock will be included.
Study design: Randomized controlled trial Study period: August 2019 to December 2021. Sample size: Assuming that the response rate is 90% with GM-CSF and 60% without GM-CSF after day 5. With alpha 5 and power 80,we need to enroll 76 cases (38 cases with each). Further assuming 20 % drop-out due to various reasons, it was decided to enroll 90 cases randomly allocated into two groups (i.e., 45 in each) by block randomization method by taking block size as 6. So for the present study, it was decided to enroll 90 cases in all.
Group A will be given Imipenem and Tigecycline. Patients with recent hospitalisation will be given Colistin in addition.
Group B will be given: To another group we will give Imipenem and Tigecycline and GMCSF.Patients with recent hospitalisation will be given Colistin in addition.
The dose of antibiotic will be given at dosage Inj Imipenem 1gm i.v. TDS Inj Tigecycline 100mg stat f/b 50mg i.v. OD Inj GM-CSF 500mcg s.c. OD Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD Monitoring and assessment At the baseline, all patients will undergo investigational evaluation as described
Daily monitoring of following parameters:
* Haemoglobin,
* Total peripheral leucocyte counts,
* Platelet counts,
* Renal function tests
* Liver function tests and
* Chest X rays will be undertaken
* Ascitic fluid analysis will be done on day 0, day 2 and day 5
Stopping rule:If the patient develops a TLC of more than 50,000, the dose of the GM CSF will be reduced to half and the treatment continued. If, even after the reduction, the TLC rises to more than 50,000, then the treatment will be stopped and the patient excluded.
Expected outcome of the project: Addition of GM-CSF to standard antibiotic regimen helps resolve SBP and improves outcome in decompensated liver cirrhotic patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
- Spontaneous Bacterial Peritonitis (SBP) with shock in a cirrhotic
- Hospital acquired SBP with shock
- Difficult to treat SBP
- Refractory Shock
- Cardiac comorbidities (known Coronary Artery Disease)
- Chronic Kidney Disease on Maintenance Hemodialysis
- < 18 years.
- Advanced Hepatocellular Carcinoma
- Post liver transplant
- HIV + ve, Immunosuppressive therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Imipenem+Tigecycline+GM-CSF GMCSF - Imipenem+Tigecycline Colistin - Imipenem+Tigecycline+GM-CSF Imipenem - Imipenem+Tigecycline+GM-CSF Tigecycline - Imipenem+Tigecycline+GM-CSF Colistin - Imipenem+Tigecycline Imipenem - Imipenem+Tigecycline Tigecycline -
- Primary Outcome Measures
Name Time Method Resolution of Spontaneous Bacterial peritonitis in both groups Day 5 Response is defined by resolution of SBP in terms of total counts \< 500,Neutrophil\<250
- Secondary Outcome Measures
Name Time Method Survival in both groups Day 28 Development of Hepatic Encephalopathy in both groups. Day 28 Hepatic Encephalopathy will be measured as per West Haven criteria
Development of organ failures in both groups. Day 28 Organ failure will be as per APACHE score
Reversal of shock in both groups Day 2 Blood pressure more than 90/60 mmHg with no inotropes requirement
Change in ascitic fluid metabolites Nitric Oxide in both groups Day 28 change is defined as percentage reduction in nitric oxide
Change in ascitic fluid macrophage population in both groups Day 28 change is defined as percentage reduction in macrophage population
Development of Pneumonia in both groups. Day 28 Pneumonia will be confirmed based on imaging and clinically
Development of Acute Kidney Injury in both groups Day 28 AKIN criteria will be used for Acute kidney injury
Resolution of Spontaneous Bacterial peritonitis in both groups Day 2 Response is defined by resolution of SBP in terms of total counts \< 500,Neutrophil\<250
Development of coagulopathy in both groups. Day 28 Coagulopathy is defined as INR \> 1.5
Trial Locations
- Locations (1)
Institute of Liver and Biliary Sciences
🇮🇳New Delhi, Delhi, India